Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGEN NASDAQ:HUMA NASDAQ:MIST NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsHUMAHumacyte$0.67+7.9%$0.92$0.55▼$2.76$138.72M2.529.43 million shs3.74 million shsMISTMilestone Pharmaceuticals$1.13-2.6%$1.30$1.00▼$3.06$144.42M0.971.07 million shs1.21 million shsUNCYUnicycive Therapeutics$5.13-5.0%$6.58$3.71▼$8.74$147.92M1.792.41 million shs631,529 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%0.00%0.00%0.00%+31.14%HUMAHumacyte0.00%-6.00%-11.83%-22.47%-75.30%MISTMilestone Pharmaceuticals0.00%-2.11%-6.45%-38.13%-26.58%UNCYUnicycive Therapeutics0.00%+0.37%-24.26%-25.31%+10.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsHUMAHumacyte$0.67+7.9%$0.92$0.55▼$2.76$138.72M2.529.43 million shs3.74 million shsMISTMilestone Pharmaceuticals$1.13-2.6%$1.30$1.00▼$3.06$144.42M0.971.07 million shs1.21 million shsUNCYUnicycive Therapeutics$5.13-5.0%$6.58$3.71▼$8.74$147.92M1.792.41 million shs631,529 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen0.00%0.00%0.00%0.00%+31.14%HUMAHumacyte0.00%-6.00%-11.83%-22.47%-75.30%MISTMilestone Pharmaceuticals0.00%-2.11%-6.45%-38.13%-26.58%UNCYUnicycive Therapeutics0.00%+0.37%-24.26%-25.31%+10.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGENFibroGen 2.00Hold$43.00340.12% UpsideHUMAHumacyte 2.75Moderate Buy$6.25827.16% UpsideMISTMilestone Pharmaceuticals 2.67Moderate Buy$7.25541.59% UpsideUNCYUnicycive Therapeutics 2.43Hold$21.75323.98% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, UNCY, MIST, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026UNCYUnicycive Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/14/2026MISTMilestone Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/8/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/1/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$18.00 ➝ $13.006/30/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/30/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $15.006/17/2026HUMAHumacyte TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.256/16/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/11/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.006/9/2026UNCYUnicycive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19HUMAHumacyte$2.04M73.36N/AN/A$0.02 per share33.71MISTMilestone Pharmaceuticals$1.55M90.76N/AN/A$0.39 per share2.90UNCYUnicycive Therapeutics$680K206.63N/AN/A$1.41 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/AHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%8/12/2026 (Estimated)UNCYUnicycive Therapeutics-$26.56M-$2.21N/A0.65N/AN/A-134.69%-84.51%8/13/2026 (Estimated)Latest FGEN, UNCY, MIST, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026UNCYUnicycive Therapeutics-$0.4710N/AN/AN/A$22.22 millionN/A8/12/2026Q2 2026MISTMilestone Pharmaceuticals-$0.18N/AN/AN/A$0.82 millionN/A8/10/2026Q2 2026HUMAHumacyte-$0.10N/AN/AN/A$1.12 millionN/A5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 million5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFGENFibroGenN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGENFibroGenN/A3.713.60HUMAHumacyte5.463.933.32MISTMilestone Pharmaceuticals1.619.189.09UNCYUnicycive TherapeuticsN/A2.402.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGENFibroGen72.71%HUMAHumacyte44.71%MISTMilestone Pharmaceuticals86.18%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipFGENFibroGen3.07%HUMAHumacyte3.10%MISTMilestone Pharmaceuticals5.03%UNCYUnicycive Therapeutics6.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGENFibroGen5704.05 million3.92 millionOptionableHUMAHumacyte150222.02 million215.14 millionOptionableMISTMilestone Pharmaceuticals30124.50 million118.24 millionOptionableUNCYUnicycive Therapeutics927.39 million25.74 millionNot OptionableFGEN, UNCY, MIST, and HUMA HeadlinesRecent News About These CompaniesCritical Comparison: Phio Pharmaceuticals (NASDAQ:PHIO) versus Unicycive Therapeutics (NASDAQ:UNCY)July 27 at 2:44 AM | americanbankingnews.comUnicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks ResearchJuly 23, 2026 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 19, 2026 | marketbeat.comUnicycive Therapeutics (UNCY) Gets a Buy from Maxim GroupJuly 16, 2026 | theglobeandmail.comUNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud InvestigationJuly 13, 2026 | globenewswire.comGuggenheim Remains a Buy on Unicycive Therapeutics (UNCY)July 10, 2026 | theglobeandmail.comUNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.July 10, 2026 | globenewswire.comUNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.July 8, 2026 | businesswire.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...July 8, 2026 | tmcnet.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmJuly 8, 2026 | businesswire.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzJuly 8, 2026 | tmcnet.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzJuly 7, 2026 | businesswire.comUNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsJuly 6, 2026 | globenewswire.comUnicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover LossesJuly 6, 2026 | newsfilecorp.comNHC Wainwright Has Negative Outlook for UNCY Q2 EarningsJuly 3, 2026 | marketbeat.comBragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the FirmJuly 2, 2026 | globenewswire.comUnicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing DeficienciesJuly 2, 2026 | finance.yahoo.comUNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudJuly 1, 2026 | businesswire.comUNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the FirmJuly 1, 2026 | globenewswire.comUS FDA declines to approve Unicycive's kidney disease drugJune 30, 2026 | reuters.comUNCY stock crashed 45% today – why did FDA reject its kidney disease NDA for a second time?June 30, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, UNCY, MIST, and HUMA Company DescriptionsFibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Humacyte NASDAQ:HUMA$0.67 +0.05 (+7.89%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.13%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Milestone Pharmaceuticals NASDAQ:MIST$1.13 -0.03 (-2.59%) Closing price 04:00 PM EasternExtended Trading$1.13 +0.00 (+0.27%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Unicycive Therapeutics NASDAQ:UNCY$5.13 -0.27 (-5.00%) Closing price 04:00 PM EasternExtended Trading$5.12 -0.01 (-0.29%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
